Oral Vinorelbine and Capecitabine as First-Line Therapy in Metastatic Breast Cancer: A Retrospective Analysis

References

• BannaGL , CollovàE , GebbiaVet al.Anticancer oral therapy: emerging related issues. Cancer Treat. Rev.36, 595–605 (2010).
   PubMed Web of Science ®Google Scholar
• CazzanigaME , DionisioMR , RivaF. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett.400, 252–258 (2017).
   PubMed Web of Science ®Google Scholar
• PajkB , CuferT , CanneyPet al.Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized Phase II trial. Breast17, 180–185 (2008).
   PubMed Web of Science ®Google Scholar
• NolèF , CataniaC , SannaGet al.Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann. Oncol.17, 322–329 (2006).
   PubMed Web of Science ®Google Scholar
• PetrelliF , DiCosimo S , LonatiV , BarniS. Vinorelbine with capecitabine, an evergreen doublet for advanced breast cancer: a systematic literature review and pooled-analysis of Phase II–III studies. Clin. Breast Cancer16, 327–334 (2016).
   PubMed Web of Science ®Google Scholar
• EisenhauerEA , TherasseP , BogaertsJet al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45, 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• HryniukWM. Average relative dose intensity and the impact on design of clinical trials. Semin. Oncol.14, 65–74 (1987).
   PubMed Web of Science ®Google Scholar
• CaparicaR , LambertiniM , de AzambujaE. How I treat metastatic triple-negative breast cancer. ESMO Open4, e000504 (2019).
   PubMed Web of Science ®Google Scholar
• GuptaGK , CollierAL , LeeDet al.Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers12(9), 2392 (2020).
   PubMed Web of Science ®Google Scholar
• MoH , XuB. Progress in systemic therapy for triple-negative breast cancer. Front. Med. doi:10.1007/s11684-020-0741-5 (2020).
   PubMed Web of Science ®Google Scholar
• CamponeM , DobrovolskayaN , TjulandinSet al.A three-arm randomized Phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast J.19, 240–249 (2013).
   PubMed Web of Science ®Google Scholar
• FinekJ , HolubecLJr , SvobodaTet al.A Phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res.29(2), 667–670 (2009).
   PubMed Web of Science ®Google Scholar
• NolèF , CrivellariD , MattioliRet al.Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother. Pharmacol.64, 673–680 (2009).
   PubMed Web of Science ®Google Scholar
• Tubiana-MathieuN , BougnouxP , BecquartDet al.All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international Phase II Trial. Br. J. Cancer101, 232–237 (2009).
   PubMed Web of Science ®Google Scholar
• GampenriederSP , BartschR , MatznellerPet al.Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer. Breast Care5, 158–162 (2010).
   PubMed Web of Science ®Google Scholar
• HassanM , OsmanMM. Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study. Hematol. Oncol. Stem Cell Ther.3, 185–190 (2010).
   PubMedGoogle Scholar
• StradaMR , PalumboR , BernardoAet al.Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2– metastatic breast cancer: joint analysis of 2 consecutive prospective Phase II trials. Clin. Breast Cancer12, 30–39 (2012).
   PubMed Web of Science ®Google Scholar
• TawfikH , RostomY , ElghazalyH. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother. Pharmacol.71, 913–919 (2013).
   PubMed Web of Science ®Google Scholar
• CinieriS , ChanA , AltundagKet al.Final results of the randomized Phase II NorCap-CA223 trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative metastatic breast cancer. Clin. Breast Cancer17, 91–99.e1 (2017).
   PubMed Web of Science ®Google Scholar
• RousseauF , RetornazF , JolyFet al.Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO). Crit. Rev. Oncol. Hematol.76, 71–78 (2010).
   PubMed Web of Science ®Google Scholar
• YangR , ShiYY , HanXH , LiuS. The impact of platinum-containing chemotherapies in advances triple-negative breast cancer: meta-analytical approach to evaluating its efficacy and safety. Oncol. Res. Treat.11, 1–10 (2021).
   Google Scholar
• BartschR. ESMO 2020: highlights in breast cancer. Memo doi:10.1007/s12254-021-00713-5 (2021).
   Google Scholar
• KumarS , BalA , DasAet al.Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. Breast Cancer Res. Treat. doi:10.1007/s10549-021-06242-3 (2021).
   Web of Science ®Google Scholar
• O'ReillyD , SendiMA , KellyCM. Overview of recent advances in metastatic triple negative breast cancer. World J. Clin. Oncol.12(3), 164–182 (2021).
   PubMed Web of Science ®Google Scholar